亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A Phase 2 Study of MORF-057, an Oral α4β7 Integrin Inhibitor in Moderately to Severely Active Ulcerative Colitis

医学 不利影响 药效学 溃疡性结肠炎 药代动力学 耐受性 内科学 临床终点 临床试验 队列 胃肠病学 疾病
作者
Bruce E. Sands,S Schreiber,Silvio Danese,Jarosław Kierkuś,Brihad Abhyankar,Michael Y. Choi,Carolyn Soo,Yujun Wu,Fangui Sun,Dooyoung Lee,Dan Cui,Maloy Mangada,Prabhat Singhal,Ali Hussain,Bruce N. Rogers,Laurent Peyrin‐Biroulet,Brian G. Feagan
出处
期刊:Clinical Gastroenterology and Hepatology [Elsevier BV]
卷期号:24 (2): 525-534 被引量:2
标识
DOI:10.1016/j.cgh.2025.07.030
摘要

MORF-057 is an orally administered small-molecule drug that inhibits α4β7 integrin-mediated recruitment of α4β7-expressing lymphocytes to the gut, a process implicated in the pathology of ulcerative colitis (UC). This study evaluated the efficacy, pharmacokinetics, pharmacodynamics, safety, and tolerability of MORF-057 in participants with moderately to severely active UC. This open-label, phase 2a, single-arm, multicenter trial comprised a 6-week screening period, a 52-week active treatment period (including a 12-week induction period and 40-week maintenance period) and a 4-week safety follow-up period. Of the 35 participants enrolled in the main cohort, 18 participants received 100 mg of oral MORF-057 twice daily for the entire treatment period. The primary efficacy endpoint was a change in the Robarts Histopathology Index (RHI) score from baseline to week 12 and was assessed in all participants with evaluable data. Additional clinical, endoscopic, and histological variables were assessed at screening and at weeks 12 and 52. MORF-057 was well tolerated, and no treatment-emergent serious adverse events were observed. At week 12, participants (n = 35) exhibited a mean (standard deviation) change from baseline in RHI score of -6.4 (11.2). Additionally, 22.9% (8/35) of participants achieved RHI remission (RHI score ≤3). In participants with evaluable data (n = 18), the effects of MORF-057 on pharmacokinetics, pharmacodynamics, and clinical efficacy were achieved at week 12 and remained consistent to week 52. Overall, this study demonstrated that oral MORF-057 is well tolerated, with promising efficacy for individuals with moderately to severely active UC. NCT05291689 CLINICAL TRIAL REGISTRY WEBSITE: https://clinicaltrials.gov/study/NCT05291689.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
lzk完成签到,获得积分10
8秒前
zzmine完成签到 ,获得积分10
13秒前
00hello00发布了新的文献求助10
19秒前
懵懂的小之完成签到,获得积分10
20秒前
田様的应助被浮云采纳,获得10
25秒前
酷波er的应助被00hello00采纳,获得10
27秒前
28秒前
33秒前
35秒前
浮云发布了新的文献求助10
38秒前
芒果完成签到,获得积分20
39秒前
47秒前
51秒前
浮云发布了新的文献求助10
55秒前
55秒前
1分钟前
1分钟前
复杂曼荷完成签到,获得积分10
1分钟前
may完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
英俊的铭的应助被邓倩采纳,获得10
1分钟前
Maestro_S的应助被呵呵采纳,获得10
1分钟前
00hello00发布了新的文献求助10
1分钟前
1分钟前
1分钟前
仁爱的鞋子完成签到,获得积分10
1分钟前
安详老鼠完成签到,获得积分10
1分钟前
2分钟前
2分钟前
Shu完成签到,获得积分10
2分钟前
刻苦的煎蛋完成签到,获得积分10
2分钟前
庾傀斗发布了新的文献求助10
2分钟前
ssgg完成签到,获得积分10
2分钟前
辛勤诗兰完成签到,获得积分10
2分钟前
2分钟前
不爱写论文完成签到,获得积分10
2分钟前
HaoZhang发布了新的文献求助10
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195111
求助须知:如何正确求助?哪些是违规求助? 9580886
关于积分的说明 21872823
捐赠科研通 7794997
什么是DOI,文献DOI怎么找? 3437934
关于科研通互助平台的介绍 2561228
邀请新用户注册赠送积分活动 2484609